ABT263s

ABT-263, also known as Navitoclax, is a potent small-molecule inhibitor that targets the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2), Bcl-xL, and Bcl-w. These proteins are crucial for cell survival and are often overexpressed in various cancers, contributing to tumor growth and resistance to chemotherapy. By inhibiting these proteins, ABT-263 promotes apoptosis, or programmed cell death, in cancer cells.

Initially developed by Abbott Laboratories (now AbbVie), ABT-263 has been investigated extensively in preclinical and clinical studies for its potential in treating a range of hematological malignancies and solid tumors. Its mechanism of action involves binding to the BH3-binding groove of Bcl-2 family proteins, disrupting their interaction with pro-apoptotic proteins like BIM, and thereby unleashing the apoptotic cascade.

While ABT-263 has shown promising anti-cancer activity, its clinical development has faced challenges, primarily due to dose-limiting toxicities, particularly thrombocytopenia (low platelet count), which is largely attributed to the inhibition of Bcl-xL. This toxicity has led to efforts to develop next-generation inhibitors that selectively target Bcl-2 while sparing Bcl-xL, or to combine ABT-263 with strategies that mitigate its side effects. Research continues to explore its therapeutic potential, often in combination regimens or with modified formulations.